Point-of-care Nucleic Acid Detection of Infectious Disease

IP Status

US Utility Patent Pending (Not Yet Published)

Inventors

​Brian J. Geiss
Charles S. Henry
David S. Dandy
Sidhartha Jain

At A Glance

​Researchers at Colorado State University have developed a novel assay to detect specific nucleic acids in patient samples.  The assay integrates multiple different types of molecular assays (padlock-rolling circle amplification, nuclease protection, lateral flow immunoassay) to detect specific nucleic acids using isothermal amplification in a format that can be detected using a simple colorimetric readout.

The assay is being developed as a point-of-care diagnostic for infection disease, including COVID-19.

Please contact our office directly for more information!

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  2020-070

Background

​Ultrasensitive sequence-specific detection of target nucleic acids has broad ranging applications in clinical diagnostics, water and food safety, environmental monitoring, biosafety and epidemiology.  With the introduction of polymerase chain reaction (PCR) and other DNA amplification techniques such as recombinase polymerase amplification, template-mediate amplification, helicase-dependent amplification, loop-medicated isothermal amplification and rolling circle amplification, significant progress has been made in the field o molecular diagnostics and nucleic acid biosensors.  However, PCR requires precise temperature control and cycling to perform DNA amplification limiting its portability and application in point-of-care diagnostics.  

Benefits
  • Detection of pathogenic nucleic acids in minimally processed tissue samples
  • Provides quick and accurate sample-to-answer results
  • Point-of-care diagnostic for infectious disease, including COVID-19
  • Portable, cost-effective, ultrasensitive

Last updated: April 2020

Add keywords or various names of inventors here (text is hidden)